Exercise-Based Pulmonary Rehabilitation for Interstitial Lung Diseases: A Review of Components, Prescription, Efficacy, and Safety
Renata G. Mendes1* 
Viviane Castello-Simões1 Renata Trimer2 
Adriana S. Garcia-Araújo1 Andrea Lucia Gonçalves Da Silva2 
Snehil Dixit3 Valéria Amorim Pires Di Lorenzo4 Bruno Archiza1 
Audrey Borghi-Silva1*- 1Cardiopulmonary Physiotherapy Laboratory, Department of Physiotherapy, Federal University of Sao Carlos (UFSCar), Sao Carlos, Brazil
- 2Cardiorespiratory Rehabilitation Laboratory, Health Sciences Department, University of Santa Cruz do Sul, Santa Cruz do Sul, Brazil
- 3Department of Medical Rehabilitation Sciences, College of Applied Medical Sciences, King Khalid University, Abha, Saudi Arabia
- 4Laboratory of Spirometry and Respiratory Physiotherapy, Department of Physiotherapy, Federal University of Sao Carlos (UFSCar), Sao Carlos, Brazil
Interstitial lung diseases (ILDs) comprise a heterogeneous group of disorders (such as idiopathic pulmonary fibrosis, sarcoidosis, asbestosis, and pneumonitis) characterized by lung parenchymal impairment, inflammation, and fibrosis. The shortness of breath (i.e., dyspnea) is a hallmark and disabling symptom of ILDs. Patients with ILDs may also exhibit skeletal muscle dysfunction, oxygen desaturation, abnormal respiratory patterns, pulmonary hypertension, and decreased cardiac function, contributing to exercise intolerance and limitation of day-to-day activities. Pulmonary rehabilitation (PR) including physical exercise is an evidence-based approach to benefit functional capacity, dyspnea, and quality of life in ILD patients. However, despite recent advances and similarities with other lung diseases, the field of PR for patients with ILD requires further evidence. This mini-review aims to explore the exercise-based PR delivered around the world and evidence supporting prescription modes, considering type, intensity, and frequency components, as well as efficacy and safety of exercise training in ILDs. This review will be able to strengthen the rationale for exercise training recommendations as a core component of the PR for ILD patients.
Definition, Types, Classification, and Epidemiology of Interstitial Lung Diseases (ILDs)
ILDs comprise a heterogeneous group of disorders that lead to diffusing inflammation and/or fibrosis of the lung parenchyma and vasculature. Classifications of ILDs are based on known (inhaled agents, drugs, infections, etc.) or unknown (idiopathic pulmonary fibrosis—IPF, sarcoidosis, asbestosis and pneumonitis) etiology, specific disease entities, or clinical, histological, or radiological patterns (1). Roughly, one-third of all diagnosed ILDs are a consequence from known exogenous and endogenous causes, whereas two-thirds are idiopathic. Nonetheless, all ILD types share a common pattern of physiological abnormalities, which is inflammation and/or fibrosis of the lung parenchyma, resulting in the presence of dyspnea, decreased pulmonary function, impaired gas exchange, reduced cardiovascular function, and exercise intolerance (2, 3).
According to the Global Burden of Disease Study (4), between the years of 1990 and 2013, there was an 86% increase in ILDs-related years of life lost, and, for the first time, among the top 50 causes of global years of life lost. The estimate for overall ILD prevalence in the United States is ~81 per 100,000 for males and ~67 per 100,000 for females per year (5). Registries conducted in Europe in 2004 involved more than 1,000 cases indicating a prevalence rate of ~17 per 100,000 inhabitants and an incidence rate of 3.62 per 100,000 per year (6, 7). However, more recent registries indicate an even higher incidence of ILDs. For instance, the estimated numbers for a registry conducted in Denmark reaches ~34 per 100,000 person-years (8).
Pathophysiology, Exercise Limitation, and Functional Impairment
The genesis of ILDs is complex and involves a series of diffuse remodeling of the lung parenchyma due to direct or systemic injury (9). In brief, the persistent inflammatory process caused by injury of the lung tissue creates a cascade of events, causing an increase in reactive oxygen species, growth factors, cytokines, and chemokine release, hence more damage is caused along with tissue fibrosis (10). Based on this, multiple consequences are observed (i.e., alveolar-capillary membrane thickening, decrease of pulmonary gas exchange, dyspnea), ultimately leading to functional impairment and exercise intolerance.
Due to the persistent inflammatory process and formation of fibrotic tissue, structural and mechanical pulmonary system alterations are observed and considered main causes of a pathological reduction of pulmonary and cardiovascular functions (11, 12). For instance, ILD patients are reported to exhibit reduced static and dynamic lung volumes (2). Moreover, the diffusing capacity is also impaired (2). Collectively, these pathological reductions in cardiopulmonary function contribute to an increase in exertional dyspnea and exercise intolerance; thus, ILD patients tend to avoid situations where they might experience breathlessness, fomenting a cycle of reduced physical activity levels and increased sedentary lifestyle (13) (see Figure 1).
Figure 1. Pathophysiology and cycle of reduced physical activity levels in ILDs.
Numerous pathophysiological responses to exercise are observed in ILD patients, such as ventilatory (i.e., abnormal breathing patterns, ventilatory inefficiency, higher oxygen cost of breathing), diffusional (i.e., impaired pulmonary gas exchange, arterial hypoxemia), cardiovascular (i.e., increased pulmonary artery pressures), and skeletal (i.e., reduced muscle strength and resistance to fatigue) dysfunctions, among others. Therefore, each patient with a diagnosis of ILD must be considered as a different and individualized organism as the contribution of each system to exercise intolerance may vary. For a comprehensive review on the topic, we direct the interested reader elsewhere (2).
Exercise Limitation In ILDs
The importance of evaluating exercise capacity in ILD patients has been investigated more recently, due to a relationship with increased survival (14). The current recommendation indicates that ILD patients have experienced exercise limitation, providing an integration of contributors to functional limitation, disease progression and enrollment in a pulmonary rehabilitation (PR) program (15, 16).
Cardiopulmonary exercise testing (CPET) provides important information concerning exertional dyspnea and mechanisms of exercise limitation as a comprehensive assessment of the physiological changes in the respiratory, cardiovascular and musculoskeletal systems during exercise, which may be also useful for exercise prescription (17–19). Maximum and peak oxygen uptake corresponding to a measurement of the capacity for aerobic activity has been linked to survival in ILD patients (18). As above mentioned, among other factors, the limitation on exercise in these patients may be the consequence of abnormal responses of gas exchange, ventilatory efficiency or ventilatory mechanical limitation (20). Older age and higher systolic pulmonary artery pressure were also independent predictors of poor submaximal exercise capacity in patients with sarcoidosis (21). However, the prognostic value of CPET parameters and responses of ILD patients remains controversial and requires additional research. Exercise tests provide a global assessment of functional capacity and this may be particularly relevant for ILDs with peripheral or respiratory muscle involvement, or where increased symptoms are not explained by changes in respiratory function variables (14).
The 6-min walk test (6MWT) is more commonly used to monitor progress of ILDs over time and during rehabilitation programs (22). Walking covered is an independent and discriminating predictor of mortality among patients with IPF (23). Oxygen desaturation impairment was associated with a 2 fold greater hazard of dying during 6 months of follow-up in IPF. This suggests that changes in the 6MWT may help to assess the costs and benefits of new therapies to individual patients of the test and individual patient characteristics (24, 25).
Peripheral muscle dysfunction is also a critical factor in determining exercise intolerance in patients with chronic lung diseases, including ILD. There are several well-established muscle dysfunction-promoting mechanisms in ILDs (26, 27). Hypoxia is one of the factors that can result in increased oxidative stress and adversely affect muscle performance (26, 27). Guler et al. (28) used a skeletal muscle index (SMI), as the sum of the muscle mass of the upper and lower limbs adjusted for height, and verified that a greater ILD severity was a significant predictor of lower SMI. Recently, pectoralis muscle area (PMA) was also associated with severity and a negative annual slope of PMA related with all-cause mortality in ILD (29). Reduced quadriceps strength has been shown to be an independent predictor of exercise capacity and more studies on the therapeutic response to muscle training are needed in this population (30).
Respiratory muscle strength may also have an impact on exercise performance (31). In sarcoidosis patients with no signs of skeletal muscle involvement, twitch mouth pressure during inspiration was a stronger predictor of distance walked during 6MWT and dyspnea than respiratory function tests or oxygenation (32, 33). Given the potential effects of physical exercise, conducting randomized clinical trials including exercise-based rehabilitation seems to be a promising field for further research. However, the interrelationship between muscle dysfunction on long-term clinical outcomes (i.e., exercise capacity, dyspnea, quality of life and mortality) need to be further explored.
PR Delivered in ILDs
Pulmonary rehabilitation (PR) for patients diagnosed with ILD are delivered in different settings and models. Traditionally, PR programs are center-based and shown positive outcomes in sarcoidosis (34) and pneumoconiosis patients (35). IPF patients have improved maximum exercise capacity and reported less shortness of breath and better quality of life after rehabilitation (36). Home-based programs are a convenient option, since they are effective, simple and an alternative for ILD patients who have restrictions accessing rehabilitation centers (37–39); moreover, this delivery model enable the interaction in order to propose changes in home environments, train family members and caregivers, as well as trying to develop skills in the patients' daily routine (37).
Most PR programs for ILD patients have a duration of 8 to 12 weeks and promote significant effects on functional capacity, quality of life and sensation of dyspnea (30, 40–46). On the other hand, short-term studies in sarcoidosis patients admitted for rehabilitation have shown benefits as reduced levels of fatigue, anxiety, depression and quality of life (34). Recently, in the face of the COVID-19 pandemic, telerehabilitation has been gaining prominence, as this strategy is safe and presents results similar to the rehabilitation programs traditionally performed in chronic respiratory disease (47), mainly in relation to the improvement of functional capacity (48). In regard to supervision, most of the studies were conducted as supervised, and higher level of improvement has been shown (6MWT) (49) in comparison with unsupervised ones, which should therefore be interpreted with caution in generalizing these findings. Besides, the effects of the intervention on exercise tolerance, health status and muscle strength are maintained after 1 year of follow-up (30).
Exercise Prescription in ILDs
There are not many randomized and controlled studies that address physical exercise on PR for various types of ILDs. Table 1 shows the prescription of exercise-based PR in ILD patients according to eight randomized controlled trials. Most studies specifically evaluated IPF patients (62.5%) (40–44) and all studies adopted aerobic training associated with strength training as the main intervention. Only one study was conducted involving inpatients (45). In the seven studies with outpatients (30, 40–44, 46), the duration of PR ranged from 8 to 12 weeks, however most studies performed it twice a week (40–44, 46). The intensity of training aerobic training was based on previous 6MWT (30, 40, 42–44, 46), heart rate (41), oxygen consumption (45), peak work rate (30, 44) and Perez-Bogerd et al. (30) have also considered Borg scale scores to increment workload of the training. Meanwhile for strength training, some studies (30, 43, 45) prescribed the exercise intensity based on repetition maximum and, peripheral muscle training was performed with a variation of 1, 2, and 3 sets of 8, 10, 12, and 15 repetitions (30, 41, 42, 44, 45); only one study described the strength training according to time (40).
Table 1. Randomized controlled trials involving exercise-based pulmonary rehabilitation in patients with interstitial lung disease.
Safety of Exercise Training for ILDs
The safety of PR in ILD patients has been poorly studied. This topic deserves attention in future clinical trials. Development of exertional hypoxemia is common in ILD patients which can lead to adverse responses (50); as premature lactic acidosis accelerating peripheral muscle fatigue and discomfort (51), reflex tachycardia and cardiac arrhythmias (52), which may even lead to fatal adverse events (53). These aspects are particularly relevant considering that a previous study demonstrated that these patients experience various periods of hypoxemia with arrhythmogenic responses during the performance of daily activities (52). In addition, there is concern regarding the safety of delivering supplemental oxygen in patients with mild and severe hypoxemia (54). This concern is based on the accumulation of evidence about the role of oxidative stress in ILD pathogenesis (55), which can be exacerbated by physical training (56) and/or oxygen supplementation (57). On the other hand, effectiveness of oxygen supplementation to correct hypoxemia during exercise is limited. For instance, Dipla et al. (58) demonstrated that the correction of using an oxygen-enriched air (FiO2 = 0.40) via a Venturi mask prevented the decline in brain oxygenation, improved muscle oxygenation, and lessened dyspnea in patients with idiopathic pulmonary fibrosis (IPF) with isolated exertional desaturation. Another study demonstrated that 40% of patients with ILD, who performed exercise with the use of a pulse demand oxygen delivery device, were not able to maintain oxygen saturation >88% (59).
In this context, a previous study (36) have observed that during the period of PR and follow-up, it was observed that there were cases of deaths; however, little has been discussed about who this subgroup was, whether they were more hypoxemic or more severely impaired in their lung function. These concerns may be particularly relevant in those patients undergoing home rehabilitation or telerehabilitation (60). Additionally, a recent meta-analysis considered the main limitation was the total absence of exacerbations and adverse events reported during rehabilitative programs in the majority of studies published (35). Considering that adverse outcomes are extremely varied, it is expected that in the future, new studies will focus on more objective criteria such as: the number of patients who were unable to maintain saturation above 88% during exercise sessions (even using oxygen supplementation), electrocardiographic abnormalities (in particular, the appearance of atrial and/or ventricular arrhythmias during or after exercise) (61), amount of oxygen administered, levels of dyspnea reported during sessions, as well as their relationship with possible adverse events, such as: exacerbations, need for medication changes and new visits to the doctor, number of hospitalizations, cardiovascular events (62), fractures, skeletal muscle injures, and deaths during the study (36). These outcomes are essential to assess with more precise and objective criteria on the safety of the different models of rehabilitation programs, as well as on the impact on the follow-up of these patients. Therefore, a more complete assessment of the safety outcomes in structured programs should be the object of future studies, given its great relevance regarding the prognosis of these patients. Finally, the long-term safety in addition to potential side effects of oxygen delivery during and after an exercise training program still needs to be assessed (54).
Adjuncts to Exercise-Based PR for ILDs
Adjunct therapies have been used during exercise-based PR of ILD patients. Currently, oxygen therapy should be prescribed for ILD patients who exhibit significant oxygen desaturation during training (<85%) (63) impacting exercise performance (64). Therefore, oxygen therapy could slow down the ventilatory limitation to exercise without altering pulmonary function or the maximal ventilatory capacity (65), which was able to promote an improvement on dyspnea (intensity and qualitative dimensions) and exercise performance in fibrotic ILD (66), and a reduction in arterial oxyhemoglobin saturation and lactic acid in ILD patients in general (67). Preliminary evidence, in fibrotic ILD patients with isolated exertional hypoxia, showed that use of portable ambulatory oxygen for 2 weeks could be an effective intervention to improvement of health-related quality of life and reduce hypoxemia and dyspnea during exertion (68). High-flow nasal cannula therapy, that manages heated and humidified air/oxygen mixtures at high flows (up to 60 L/min) (69), has been gaining popularity and is subject of recent research in patients with ILD (70–72). This technique improves ventilatory efficiency and reduces the work of breathing, generating a positive end-expiratory pressure, which may counterbalance auto-positive end-expiratory pressure, improving the oxygenation and increasing airway patency during expiration (69), being an interesting option during PR; although its benefits to exercise capacity have been proven in this population (70, 73), its effectiveness in relation to standard oxygen therapy needs further clarifications.
Non-invasive ventilation is another adjunct option during PR (74–76). Moderno et al. (75) evaluated ILD patients during three submaximal exercise tests (60% of maximum load) in three different situations: with proportional assist ventilation, with continuous positive airway pressure and without ventilatory support; the results suggest that patients on proportional assist ventilation had greater increased exercise tolerance and reduction in oxygenation and dyspnea. In addition, preliminary data (74) showed that patients with chronic hypercapnic ILD were able to benefit from nocturnal non-invasive ventilation and thus increase their physical performance and health-related quality of life. These preliminary results suggest that non-invasive ventilation may increase acutely exercise tolerance, decrease dyspnea, cardiac effort and improve the quality of life in this population. However, the chronic effects of this type of intervention on exercise responses, as well as the combination with PR, need further research.
Another adjunctive intervention for use within rehabilitation programs is neuromuscular electrical stimulation (NMES), which may be an effective treatment for muscle weakness in adults with advanced chronic respiratory disease, such as ILD (77). This modality applied prior to endurance training in patients with cystic fibrosis and severe pulmonary obstruction, is able to strengthen the peripheral muscles, improves the quality of life, reduce the ventilation required during exertion and improve the insulin resistance (78). A previous report (79) demonstrated that NMES applied on bilateral quadriceps femoris, at 40 Hz/20 min for 3 days/week during 6 weeks, associated with respiratory exercises was able to improve functional exercise capacity and prevent quadriceps weakness in ILD patients. Although adjunctive therapy is an important component of PR, more studies are necessary to define the best option related to cost, short- and long-term clinical effectiveness and prognosis.
Conclusions and Potential Future Developments of Exercise-Based PR for ILDs
PR is an important part of comprehensive care for ILD patients in a similar way to chronic obstructive pulmonary disease patients (63). Despite evidence of the benefits of PR in ILD, this field has yet to evolve. Important issues yet to be addressed include methods to extend the duration of the benefit; and how PR can best be adapted to the complex needs of people with ILD (30). In order for these patients to benefit from the effects of PR, some barriers and facilitators need to be discussed (80).
The main barriers to the participation of patients with ILD in PR or even to the practice of physical exercises are non-adherence due to lack of understanding and the low benefits perceived by non-respondents (67). In this context, identifying the associated comorbidities, the heterogeneous clinical course of ILD and the limitations of physical exercise capacity in the physical evaluation of these patients can minimize these barriers. It is also worth mentioning that, many times, these patients are not referred to rehabilitation centers, or even have mobility and/or financial difficulties, related to the cost of transportation, especially if the individual is a home user of oxygen (80).
It is also important to consider individual aspects as barriers, such as the age of the patient, who are often patients who work, the very lack of access, the need to prescribe oxygen therapy and the difficulty of following a physical rehabilitation program (81). Another aspect that directly influences these barriers is the fear and /or lack of knowledge of family and friends concerning the physical and emotional limitations of the patient with ILD.
On the other hand, given the positive impact of PR, efforts should be made to ensure that PR is widely available across the spectrum of ILD. As facilitators, it would be important to include strategies to improve the quality of information to patients and education of medical professionals on the importance and benefits of PR, which could improve adherence rates.
It is also important to include strategies to improve the selection of these patients and more health education for patients, families, and professionals on the adequacy of referrals to avoid non-adherence to PR. Education about the importance of routine and/or self-care of physical exercises has been considered an important facilitator, however, the inclusion of this routine is influenced by the family and professional lives of individuals.
No less important, we have to propose facilitators regarding low-cost strategies and alternatives for carrying out physical training in a PR as well as maintaining the benefits achieved, considering the lack of rehabilitation centers to meet the demand of patients with chronic respiratory diseases in several regions and municipalities, mainly in the interior cities (41, 69). In addition to the limitation of displacement, due to distance, physical tiredness, the limitation of mobility imposed by the disease, hindering its availability and access.
Finally, barriers and facilitators involve physical, psychological, social, and motivational issues that require planning health costs so that the PR can offer integrated care to a larger number of patients and thus strengthen the recommendations for physical training as a central component of PR for patients with ILD.
Author Contributions
RGM and AB-S: study conception and design. RGM, VC-S, RT, AG-A, ALGDS, SD, VAPDL, BA, and AB-S: analysis and interpretation of results and draft manuscript preparation. All authors reviewed the results and approved the final version of the manuscript.
Funding
This work was supported by Fundação de Amparo à Pesquisa do Estado de São Paulo, N° do Processo FAPESP: 2015/26501-1 (Projects financer) and Capes finance code 001 (scholarship of VC-S and BA).
Conflict of Interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher's Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Acknowledgments
The authors would like to thank the FAPESP and CAPES.
Abbreviations
6MWT, 6-minute walk test; CG, control group; COPD, chronic respiratory disease; CTD-ILD, connective tissue disease-related ILD; ET, exercise training; ESWT, endurance shuttle walk test; HRQoL, health-related quality of life; ILD, interstitial lung disease; IPAQ, International Physical Activity Questionnaire; IPF, idiopathic pulmonary fibrosis; PR, pulmonary rehabilitation; RCT, randomized controlled trial; RM, repetition maximum; SGRQ-I, St George Respiratory Questionnaire for IPF.
References
1. Demedts M, Wells AU, Antó JM, Costabel U, Hubbard R, Cullinan P, et al. Interstitial lung diseases: an epidemiological overview. Eur Respir J. (2001) 18:2–16.
2. Molgat-Seon Y, Schaeffer MR, Ryerson CJ, Guenette JA. Exercise pathophysiology in interstitial lung disease. Clin Chest Med. (2019) 40:405–20. doi: 10.1016/j.ccm.2019.02.011
3. Antoniou KM, Margaritopoulos GA, Tomassetti S, Bonella F, Costabel U, Poletti V. Interstitial lung disease. Eur Respir Rev. (2014) 23:40–54. doi: 10.1183/09059180.00009113
4. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. (2015) 385:117–71. doi: 10.1016/S0140-6736(14)61682-2
5. Coultas DB, Zumwalt RE, Black WC, Sobonya RE. The epidemiology of interstitial lung diseases. Am J Respir Crit Care Med. (1994) 150:967–72. doi: 10.1164/ajrccm.150.4.7921471
6. Karakatsani A, Papakosta D, Rapti A, Antoniou KM, Dimadi M, Markopoulou A, et al. Epidemiology of interstitial lung diseases in Greece. Respir Med. (2009) 103:1122–9. doi: 10.1016/j.rmed.2009.03.001
7. López-Campos JL, Rodríguez-Becerra E. Incidence of interstitial lung diseases in the south of Spain 1998-2000: the RENIA study. Eur J Epidemiol. (2004) 19:155–61. doi: 10.1023/B:EJEP.0000017660.18541.83
8. Kornum JB, Christensen S, Grijota M, Pedersen L, Wogelius P, Beiderbeck A, et al. The incidence of interstitial lung disease 1995-2005: a Danish nationwide population-based study. BMC Pulm Med. (2008) 8:24. doi: 10.1186/1471-2466-8-24
9. Tinghe RM, Noble PW. Inflammation in the pathogenesis of interstitial lung disease. In: Schwarz MI, King TE, editors. Interstitial Lung Disease. 5th ed. Shelton, CT: People's Medical Publishing House (2011). p. 281–314.
10. Bagnato G, Harari S. Cellular interactions in the pathogenesis of interstitial lung diseases. Eur Respir Rev. (2015) 24:102–14. doi: 10.1183/09059180.00003214
11. Baydur A. Pulmonary physiology in interstitial lung disease: recent developments in diagnostic and prognostic implications. Curr Opin Pulm Med. (1996) 2:370–5. doi: 10.1097/00063198-199609000-00005
12. Panagiotou M, Church AC, Johnson MK, Peacock AJ. Pulmonary vascular and cardiac impairment in interstitial lung disease. Eur Respir Rev. (2017) 26:160053. doi: 10.1183/16000617.0053-2016
13. Nishiyama O, Yamazaki R, Sano H, Iwanaga T, Higashimoto Y, Kume H, et al. Physical activity in daily life in patients with idiopathic pulmonary fibrosis. Respir Investig. (2018) 56:57–63. doi: 10.1016/j.resinv.2017.09.004
14. Holland AE. Exercise limitation in interstitial lung disease - mechanisms, significance and therapeutic options. Chron Respir Dis. (2010) 7:101–11. doi: 10.1177/1479972309354689
15. Wells AU, Hirani N. Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax. (2008) 63:v1–58. doi: 10.1136/thx.2008.101691
16. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. (2011) 183:788–824. doi: 10.1164/rccm.2009-040GL
17. Nakayama M, Bando M, Araki K, Sekine T, Kurosaki F, Sawata T, et al. Physical activity in patients with idiopathic pulmonary fibrosis. Respirology. (2015) 20:640–6. doi: 10.1111/resp.12500
18. Fell CD, Liu LX, Motika C, Kazerooni EA, Gross BH, Travis WD, et al. The prognostic value of cardiopulmonary exercise testing in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. (2009) 179:402–7. doi: 10.1164/rccm.200802-241OC
19. Molgat-Seon Y, Schaeffer MR, Ryerson CJ, Guenette JA. Cardiopulmonary exercise testing in patients with interstitial lung disease. Front Physiol. (2020) 11:832. doi: 10.3389/fphys.2020.00832
20. Bonini M, Fiorenzano G. Exertional dyspnoea in interstitial lung diseases: the clinical utility of cardiopulmonary exercise testing. Eur Respir Rev. (2017) 26:160099. doi: 10.1183/16000617.0099-2016
21. Ozen DK, Mutlu B, Kocakaya D, Turan B, Sekerci SS, Ceyhan B, et al. The effect of global longitudinal strain on impaired six-minute walk test performance in patients with sarcoidosis. Sarcoidosis Vasc Diffus Lung Dis. (2020) 37:66–73. doi: 10.36141/svdld.v37i1.8802
22. Eaton T, Young P, Milne D, Wells AU. Six-minute walk, maximal exercise tests: reproducibility in fibrotic interstitial pneumonia. Am J Respir Crit Care Med. (2005) 171:1150–7. doi: 10.1164/rccm.200405-578OC
23. Lama VN, Flaherty KR, Toews GB, Colby T V., Travis WD, Long Q, et al. Prognostic value of desaturation during a 6 minute walk test in idiopathic interstitial pneumonia. Am J Respir Crit Care Med. (2003) 168:1084–90. doi: 10.1164/rccm.200302-219OC
24. Lettieri CJ, Nathan SD, Browning RF, Barnett SD, Ahmad S, Shorr AF. The distance-saturation product predicts mortality in idiopathic pulmonary fibrosis. Respir Med. (2006) 100:1734–41. doi: 10.1016/j.rmed.2006.02.004
25. Flaherty KR, Andrei AC, Murray S, Fraley C, Colby T V., Travis WD, et al. Idiopathic pulmonary fibrosis: prognostic value of changes in physiology and six-minute-walk test. Am J Respir Crit Care Med. (2006) 174:803–9. doi: 10.1164/rccm.200604-488OC
26. Weisman IM, Weisman IM, Marciniuk D, Martinez FJ, Sciurba F, Sue D, et al. ATS/ACCP Statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med. (2003) 167:211–77. doi: 10.1164/ajrccm.167.10.952
27. Mador MJ, Bozkanat E. Skeletal muscle dysfunction in chronic obstructive pulmonary disease. Respir Res. (2001) 2:216–24. doi: 10.1186/rr60
28. Guler SA, Hur SA, Lear SA, Camp PG, Ryerson CJ. Body composition, muscle function, and physical performance in fibrotic interstitial lung disease: a prospective cohort study. Respir Res. (2019) 20:1–9. doi: 10.1186/s12931-019-1019-9
29. Molgat-Seon Y, Guler SA, Peters CM, Vasilescu DM, Puyat JH, Coxson HO, et al. Pectoralis muscle area and its association with indices of disease severity in interstitial lung disease. Respir Med. (2021) 186:106539. doi: 10.1016/j.rmed.2021.106539
30. Perez-Bogerd S, Wuyts W, Barbier V, Demeyer H, Van Muylem A, Janssens W, et al. Short and long-term effects of pulmonary rehabilitation in interstitial lung diseases: a randomised controlled trial. Respir Res. (2018) 19:182. doi: 10.1186/s12931-018-0884-y
31. Kabitz HJ, Lang F, Walterspacher S, Sorichter S, Müller-Quernheim J, Windisch W. Impact of impaired inspiratory muscle strength on dyspnea and walking capacity in sarcoidosis. Chest. (2006) 130:1496–502. doi: 10.1378/chest.130.5.1496
32. Pietro KM, Ricardo G, Rui GPND, Marcelo BG, Fernando FG, Bruno H, et al. Relationship of pectoralis muscle area and skeletal muscle strength with exercise tolerance and dyspnea in interstitial lung disease. Sarcoidosis Vasc Diffus Lung Dis. (2017) 34:200–8. doi: 10.36141/svdld.v34i3.5384
33. Karadalli MN, Boşnak-Güçlü M, Camcioglu B, Kokturk N, Tüktaş H. Effects of inspiratory muscle training in subjects with sarcoidosis: a randomized controlled clinical trial. Respir Care. (2016) 61:483–94. doi: 10.4187/respcare.04312
34. Lingner H, Buhr-Schinner H, Hummel S, Van Der Meyden J, Grosshennig A, Nowik D, et al. Short-term effects of a multimodal 3-week inpatient pulmonary rehabilitation programme for patients with sarcoidosis: the ProKaSaRe study. Respiration. (2018) 95:343–53. doi: 10.1159/000486964
35. Zhao H, Xie Y, Wang J, Li X, Li J. Pulmonary rehabilitation can improve the functional capacity and quality of life for pneumoconiosis patients: a systematic review and meta-analysis. Biomed Res Int. (2020) 2020:6174936. doi: 10.1155/2020/6174936
36. Dowman L, Hill CJ, Holland AE. Pulmonary rehabilitation for interstitial lung disease. Cochrane Database Syst Rev. (2014) CD006322. doi: 10.1002/14651858.CD006322.pub3
37. Tsang EW, Kwok H, Chan AKY, Choo KL, Chan KS, Lau KS, et al. Outcomes of community-based and home-based pulmonary rehabilitation for pneumoconiosis patients: a retrospective study. BMC Pulm Med. (2018) 18:133. doi: 10.1186/s12890-018-0692-7
38. Ozalevli S, Karaali HK, Ilgin D, Ucan ES. Effect of home-based pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis. Multidiscip Respir Med. (2010) 5:31–7. doi: 10.1186/2049-6958-5-1-31
39. Wallaert B, Duthoit L, Drumez E, Behal H, Wemeau L, Chenivesse C, et al. Long-term evaluation of home-based pulmonary rehabilitation in patients with fibrotic idiopathic interstitial pneumonias. ERJ Open Res. (2019) 5:00045-2019. doi: 10.1183/23120541.00045-2019
40. Nishiyama O, Kondoh Y, Kimura T, Kato K, Kataoka K, Ogawa T, et al. Effects of pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis. Respirology. (2008) 13:394–9. doi: 10.1111/j.1440-1843.2007.01205.x
41. Gaunaurd IA, Gómez-Marín OW, Ramos CF, Sol CM, Cohen MI, Cahalin LP, et al. Physical activity and quality of life improvements of patients with idiopathic pulmonary fibrosis completing a pulmonary rehabilitation program. Respir Care. (2014) 59:1872–9. doi: 10.4187/respcare.03180
42. Jackson RM, Gómez-Marín OW, Ramos CF, Sol CM, Cohen MI, Gaunaurd IA, et al. Exercise limitation in IPF patients: a randomized trial of pulmonary rehabilitation. Lung. (2014) 192:367–76. doi: 10.1007/s00408-014-9566-9
43. Dowman LM, McDonald CF, Hill CJ, Lee AL, Barker K, Boote C, et al. The evidence of benefits of exercise training in interstitial lung disease: a randomised controlled trial. Thorax. (2017) 72:610–9. doi: 10.1136/thoraxjnl-2016-208638
44. Vainshelboim B, Oliveira J, Fox BD, Soreck Y, Fruchter O, Kramer MR. Long-term effects of a 12-week exercise training program on clinical outcomes in idiopathic pulmonary fibrosis. Lung. (2015) 193:345–54. doi: 10.1007/s00408-015-9703-0
45. Greening NJ, Williams JEA, Hussain SF, Harvey-Dunstan TC, Bankart MJ, Chaplin EJ, et al. An early rehabilitation intervention to enhance recovery during hospital admission for an exacerbation of chronic respiratory disease: randomised controlled trial. BMJ. (2014) 349:g4315. doi: 10.1136/bmj.g4315
46. Holland AE, Hill CJ, Conron M, Munro P, McDonald CF. Short term improvement in exercise capacity and symptoms following exercise training in interstitial lung disease. Thorax. (2008) 63:549–54. doi: 10.1136/thx.2007.088070
47. Cox NS, Dal Corso S, Hansen H, McDonald CF, Hill CJ, Zanaboni P, et al. Telerehabilitation for chronic respiratory disease. Cochrane Database Syst Rev. (2021) 1:CD013040. doi: 10.1002/14651858.CD013040.pub2
48. Cerdán-de-Las-Heras J, Balbino F, Løkke A, Catalán-Matamoros D, Hilberg O, Bendstrup E. Tele-rehabilitation program in idiopathic pulmonary fibrosis-a single-center randomized trial. Int J Environ Res Public Health. (2021) 18:10016.
49. Vainshelboim B. Exercise training in idiopathic pulmonary fibrosis: is it of benefit? Breathe. (2016) 12:130–8. doi: 10.1183/20734735.006916
50. Garvey C, Tiep B, Carter R, Barnett M, Hart M, Casaburi R. Severe exercise-induced hypoxemia. Respir Care. (2012) 57:1154–60. doi: 10.4187/respcare.01469
51. Vogiatzis I, Zakynthinos S. Factors limiting exercise tolerance in chronic lung diseases. Compr Physiol (2012) 2:1779–817. doi: 10.1002/cphy.c110015
52. Park JH, Jegal Y, Shim TS, Lim CM, Lee S Do, Koh Y, et al. Hypoxemia and arrhythmia during daily activities and six-minute walk test in fibrotic interstitial lung diseases. J Korean Med Sci. (2011) 26:372–8. doi: 10.3346/jkms.2011.26.3.372
53. Vahdatpour CA, Luebbert JJ, Palevsky HI. Atrial arrhythmias in chronic lung disease-associated pulmonary hypertension. Pulm Circ. (2020) 10:2045894020910685. doi: 10.1177/2045894020910685
54. Schaeffer MR, Molgat-Seon Y, Ryerson CJ, Guenette JA. Supplemental oxygen for the management of dyspnea in interstitial lung disease. Curr Opin Support Palliat Care. (2019) 13:174–8. doi: 10.1097/SPC.0000000000000434
55. Kinnula VL, Fattman CL, Tan RJ, Oury TD. Oxidative stress in pulmonary fibrosis: a possible role for redox modulatory therapy. Am J Respir Crit Care Med. (2005) 172:417–22. doi: 10.1164/rccm.200501-017PP
56. Jackson R, Ramos C, Gupta C, Gomez-Marin O. Exercise decreases plasma antioxidant capacity and increases urinary isoprostanes of IPF patients. Respir Med. (2010) 104:1919–28. doi: 10.1016/j.rmed.2010.07.021
57. Carpagnano GE, Kharitonov SA, Foschino-Barbaro MP, Resta O, Gramiccioni E, Barnes PJ. Supplementary oxygen in healthy subjects and those with COPD increases oxidative stress and airway inflammation. Thorax. (2004) 59:1016–9. doi: 10.1136/thx.2003.020768
58. Dipla K, Boutou AK, Markopoulou A, Pitsiou G, Papadopoulos S, Chatzikosti A, et al. Exertional desaturation in idiopathic pulmonary fibrosis: the role of oxygen supplementation in modifying cerebral-skeletal muscle oxygenation and systemic hemodynamics. Respiration. (2021) 100:463–75. doi: 10.1159/000514320
59. Martí S, Pajares V, Morante F, Ramón MA, Lara J, Ferrer J, et al. Are oxygen-conserving devices effective for correcting exercise hypoxemia? Respir Care. (2013) 58:1606–13. doi: 10.4187/respcare.02260
60. Lewis A, Knight E, Bland M, Middleton J, Mitchell E, McCrum K, et al. Feasibility of an online platform delivery of pulmonary rehabilitation for individuals with chronic respiratory disease. BMJ Open Respir Res. (2021) 8:e000880. doi: 10.1136/bmjresp-2021-000880
61. Vainshelboim B, Dobin G, Myers J, Oliveira J, Unterman A, Izhakian S, et al. Safety of exertional desaturation in idiopathic pulmonary fibrosis: An electrocardiography study. Clin Respir J. (2018) 12:2426–32. doi: 10.1111/crj.12924
62. Holland A, Hill C. Physical training for interstitial lung disease. Cochrane Database Syst Rev. (2008) 4:CD006322. doi: 10.1002/14651858.CD006322.pub2
63. Nakazawa A, Cox NS, Holland AE. Current best practice in rehabilitation in interstitial lung disease. Ther Adv Respir Dis. (2017) 11:115–28. doi: 10.1177/1753465816676048
64. Harris-Eze AO, Sridhar G, Clemens RE, Gallagher CG, Marciniuk DD. Oxygen improves maximal exercise performance in interstitial lung disease. Am J Respir Crit Care Med. (1994) 150:1616–22. doi: 10.1164/ajrccm.150.6.7952624
65. Spruit MA, Singh SJ, Garvey C, Zu Wallack R, Nici L, Rochester C, et al. An official American thoracic society/European respiratory society statement: key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med. (2013) 188:e13–64. doi: 10.1164/rccm.201309-1634ST
66. Bye PTP, Anderson SD, Woolcock AJ, Young IH, Alison JA. Bicycle endurance performance of patients with interstitial lung disease breathing air and oxygen. Am Rev Respir Dis. (1982) 126:1005–12.
67. Schaeffer MR, Ryerson CJ, Ramsook AH, Molgat-Seon Y, Wilkie SS, Dhillon SS, et al. Effects of hyperoxia on dyspnoea and exercise endurance in fibrotic interstitial lung disease. Eur Respir J. (2017) 49:1602494. doi: 10.1183/13993003.02494-2016
68. Visca D, Mori L, Tsipouri V, Fleming S, Firouzi A, Bonini M, et al. Effect of ambulatory oxygen on quality of life for patients with fibrotic lung disease (AmbOx): a prospective, open-label, mixed-method, crossover randomised controlled trial. Lancet Respir Med. (2018) 6:759–70. doi: 10.1016/S2213-2600(18)30289-3
69. Spoletini G, Alotaibi M, Blasi F, Hill NS. Heated humidified high-flow nasal oxygen in adults: mechanisms of action and clinical implications. Chest. (2015) 148:253–61. doi: 10.1378/chest.14-2871
70. Suzuki A, Ando M, Kimura T, Kataoka K, Yokoyama T, Shiroshita E, et al. The impact of high-flow nasal cannula oxygen therapy on exercise capacity in fibrotic interstitial lung disease: a proof-of-concept randomized controlled crossover trial. BMC Pulm Med. (2020) 20:51. doi: 10.1186/s12890-020-1093-2
71. Koyauchi T, Hasegawa H, Kanata K, Kakutani T, Amano Y, Ozawa Y, et al. Efficacy and tolerability of high-flow nasal cannula oxygen therapy for hypoxemic respiratory failure in patients with interstitial lung disease with do-not-intubate orders: a retrospective single-center study. Respiration. (2018) 96:323–9. doi: 10.1159/000489890
72. Koyauchi T, Yasui H, Enomoto N, Hasegawa H, Hozumi H, Suzuki Y, et al. Pulse oximetric saturation to fraction of inspired oxygen (SpO2/FIO2) ratio 24 hours after high-flow nasal cannula (HFNC) initiation is a good predictor of HFNC therapy in patients with acute exacerbation of interstitial lung disease. Ther Adv Respir Dis. (2020) 14:1–11. doi: 10.1177/1753466620906327
73. Arizono S, Oomagari M, Yanagita Y, Machiguchi H, Tawara Y, Yokomura K. Benefits of high-flow nasal cannula oxygen therapy on exercise capacity following acute exacerbation in ILD patients. Eur Respir J. (2020) 56:4662. doi: 10.1183/13993003.congress-2020.4662
74. Heinzelmann I, Gloeckl R, Dreher M, Ekkernkamp E, Schmoor C, Schoenheit-Kenn U, et al. Feasibility and effects of non-invasive ventilation during pulmonary rehabilitation in patients with hypercapnic interstitial lung disease. Eur Respir J. (2014) 44(Suppl. 58):P627.
75. Moderno E V., Yamaguti WPS, Schettino GPP, Kairalla RA, Martins MA, Carvalho CRR, et al. Effects of proportional assisted ventilation on exercise performance in idiopathic pulmonary fibrosis patients. Respir Med. (2010) 104:134–41. doi: 10.1016/j.rmed.2009.08.001
76. Dreher M, Ekkernkamp E, Schmoor C, Schoenheit-Kenn U, Winterkamp S, Kenn K. Pulmonary rehabilitation and noninvasive ventilation in patients with hypercapnic interstitial lung disease. Respiration. (2015) 89:208–13. doi: 10.1159/000369862
77. Ambrosino N, Fracchia C. Strategies to relieve dyspnoea in patients with advanced chronic respiratory diseases. A narrative review. Pulmonology. (2019) 25:289–98. doi: 10.1016/j.pulmoe.2019.04.002
78. Vivodtzev I, Decorte N, Wuyam B, Gonnet N, Durieu I, Levy P, et al. Benefits of neuromuscular electrical stimulation prior to endurance training in patients with cystic fibrosis and severe pulmonary dysfunction. Chest. (2013) 143:485–93. doi: 10.1378/chest.12-0584
79. Camcioglu B, Güçlü MB, Keleş MN, Oskay D, Türktaş H. Effects of neuromuscular electrical stimulation on functional exercise capacity, respiratory and peripheral muscle strength in patients with interstitial lung disease: a preliminary report. Eur Respir J. (2017) 50:PA2541. doi: 10.1183/1393003.congress-2017.PA2541
80. McCarron EP, Bailey M, Leonard B, McManus TE. Improving the uptake: barriers and facilitators to pulmonary rehabilitation. Clin Respir J. (2019) 13:624–9. doi: 10.1111/crj.13068
81. Spielmanns M, Gloeckl R, Schmoor C, Windisch W, Storre JH, Boensch M, et al. Effects on pulmonary rehabilitation in patients with COPD or ILD: a retrospective analysis of clinical and functional predictors with particular emphasis on gender. Respir Med (2016) 113:8–14. doi: 10.1016/j.rmed.2016.02.006
Keywords: physical exercise, rehabilitation, respiratory disease, exercise intolerance dyspnea, interstitial lung disease
Citation: Mendes RG, Castello-Simões V, Trimer R, Garcia-Araújo AS, Gonçalves Da Silva AL, Dixit S, Di Lorenzo VAP, Archiza B and Borghi-Silva A (2021) Exercise-Based Pulmonary Rehabilitation for Interstitial Lung Diseases: A Review of Components, Prescription, Efficacy, and Safety. Front. Rehabilit. Sci. 2:744102. doi: 10.3389/fresc.2021.744102
Received: 19 July 2021; Accepted: 21 October 2021;
Published: 16 November 2021.
Edited by:
Anne Holland, Monash University, AustraliaReviewed by:
Jordan A. Guenette, University of British Columbia, CanadaMarcelo Velloso, Federal University of Minas Gerais, Brazil
Copyright © 2021 Mendes, Castello-Simões, Trimer, Garcia-Araújo, Gonçalves Da Silva, Dixit, Di Lorenzo, Archiza and Borghi-Silva. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Renata G. Mendes, renatamendes@ufscar.br; Audrey Borghi-Silva, audrey@ufscar.br